

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: **Monday, December 29, 2025**
Time: 10:00 am Eastern Time
Location: Zoom Teleconference
Institution: Hackensack Meridian Health, Hackensack, NJ
Principal Investigator: **Andrew Ip, MD**
Protocol: Lyell Immunopharma, Inc., **LYL314-101**
NCT Number: NCT05826535
Meeting Type: Initial Review of Protocol and Site
Title: A phase 1/2 multi-center study evaluating the safety and efficacy of IMPT-314, a CD19/20 bispecific chimeric antigen receptor (CAR) T cell therapy in participants with relapsed or refractory aggressive B-cell non-hodgkin lymphoma.

1. Call to order:

The Meeting was called to order at 9:59 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Six voting members were present, including two local members unaffiliated with the institution and the Institution's Biosafety Officer. Also present was IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Review of proposed research:

The Chair provided an overview of the protocol.

The Chair provided an overview of the biosafety risk assessment for the protocol.

7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-2 containment facilities and practices** are required for LYL314 since it consists of autologous T cells modified by a recombinant, replication-defective lentiviral vector.

The Committee determined that IBC oversight will continue for **3 months after the last subject's last dose of LYL314 locally**, provided all other criteria for study closure are met.

8. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6

NO: 0

ABSTAIN: 0

9. Review of Principal Investigator qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

Point of Discussion:

1. The Committee discussed that the Principal Investigator's CV does not note that he is currently licensed to practice medicine in the state of New Jersey. The Committee recommended that an updated CV including this information be provided to IBC Services.

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. The Committee had no questions or concerns about the facilities and practices.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 6

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 10:08 am Eastern Time.